Diabetes

New research suggests immunosuppressants do not increase the risk of COVID-19.

The objective of the study was to evaluate the impact of the ambulatory care pharmacist intervention on A1C changes in patients with uncontrolled type 2 diabetes mellitus (T2DM) during a 2-year period at the diabetes education center.

Educating patients about medication adherence and understanding and monitoring A1C and fasting glucose levels improves health outcomes.

Amphastar Pharmaceuticals’ generic glucagon for injection USP, 1 mg/vial packaged in an emergency kit, is indicated for the treatment of severe hypoglycemia, which may occur in patients with diabetes mellitus.

There are compelling reasons to use sodium-glucose cotransporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes, according to a session at the 2020 ASHP Midyear Clinical Meeting and Exhibition.

Even when all 5 factors were optimally controlled, patients with type 2 diabetes still had a 21% higher risk for CVD and a 31% higher risk for heart failure hospitalization compared to patients without diabetes.

In the midst of the COVID-19 pandemic, it is important that individuals who are at higher risk for poor outcomes from infection with vaccine-preventable diseases remain up-to-date with their immunizations.

Examining several biomarkers to look for biological explanations for these results, the research team found key mechanisms, including insulin resistance, body mass index (BMI), lipoprotein metabolism, and inflammation, according to the study authors.

Results from 2 pooled post-hoc analyses of phase 3 ORION-9, -10, and -11 trials evaluating inclisiran demonstrated the treatment was well-tolerated and effective.

Biological processes may be limiting the ability of insulin to adapt to obesity, rendering most people vulnerable to type 2 diabetes.

Through Project IMPACT: Diabetes Prevention, the APhA Foundation has built the infrastructure that allows the National DPP to be offered using an innovative service model.

The drug combination of dapagliflozin and exenatide continues to stay effective without a loss of effect after 2 years of continual use in patients with type 2 diabetes (T2D), according to researchers at Thomas Jefferson University.

Further research is essential in order to determine the relationship between diabetes and COVID-19 and what impact glucose-lowering drugs may have.

For patients with type 1 and type 2 diabetes, these computerized devices offer a break from conventional daily injections, while allowing patients to still reach and maintain their A1c levels and blood sugar targets.

Dogs and Cats have different blood make-ups and need a specifically calibrated device for glucose monitoring to manage diabetes.

The research found that obese patients with diabetes were significantly less likely to develop pancreatic cancer if they had undergone bariatric surgery, with the majority of the patients in the study being female.

Insulin prices are 8 times higher in the United States than 32 other high-income countries combined.

Integrating specialty pharmacy staff into oncology, neurology, rheumatology, and other specialty clinics within their health systems is a growing trend with a range of beneficial outcomes.

The Rare and Atypical Diabetes Network (RADIANT) plans to screen approximately 2000 people with unknown or atypical forms of diabetes that do not fit the common features of type 1 diabetes (T1D) and type 2 diabetes (T2D).

Two groups of medications that are generally prescribed to treat type 2 diabetes have been found to reduce risks associated with chronic kidney disease and cardiovascular disease.

Inflammation caused by rheumatoid arthritis may increase the risk of type 2 diabetes.

Children with a previous diabetes diagnosis showed lower performances compared with newly diagnosed children, suggesting that the deficits may worsen over time.

Researchers at Duke University have found that the efficacy of a 2-pronged type 2 diabetes (T2D) treatment increases when the drugs are linked by a heat-sensitive tether rather than simply being concurrently administered, according to a press release.

In recent years, many improvements have been made in the continuous glucose monitoring arena for individuals with diabetes, and there are more products on the horizon.

A simple test may be a low-cost way of identifying patients at-risk for type 2 diabetes.